2022 Safinamide(Parkinson’s Disease) - Forecast and Market Analysis - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

2022 Safinamide(Parkinson’s Disease) - Forecast and Market Analysis

Description:

Get a detailed report at . In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug. – PowerPoint PPT presentation

Number of Views:110

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: 2022 Safinamide(Parkinson’s Disease) - Forecast and Market Analysis


1
Safinamide (Parkinsons Disease) Forecast and
Market Analysis to 2022
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_marketoptimizer.org with
your contact details and questions if any.
  • Published Mar 2014
  • Single User PDF US 3495
  • Corporate User PDF US 10485

2
Safinamide (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • Parkinsons disease is a progressive condition
    that is characterized by bradykinesia, muscular
    rigidity, tremor, and postural instability. As
    the second most common neurodegenerative
    disorder, Parkinsons disease may affect
    individuals of any age but prevalence is
    increased with age and it is most common in the
    elderly. Dopaminergic therapies have been fairly
    effective in treating bradykinesia, but several
    unmet needs remain. Some needs will be met during
    the forecast period from 2012-2022, while others,
    such as the need for disease-modifying drugs,
    will remain.
  • Researcher expects that advancements will be made
    in levodopa administration and that four new
    molecular entities will be introduced to the
    market by 2022, these factors along with
    increased patient numbers from an aging
    population will drive the market during the
    forecast period.

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
3
Safinamide (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • In 2012, Newron completed Phase III clinical
    trials for safinamide, a dual-mechanism
    a-aminoamide derivative, acting as an MAO-B and
    glutamate release inhibitor (EPDA, press release,
    May 14, 2012).
  • In 2006, Merck Serono (a division of Merck KGaA)
    had acquired the exclusive worldwide rights for
    safinamide however, in 2011 the deal was
    terminated, seeing Merck returning the compound
    to Newron due to concerns over the potential
    market size for the drug.
  • Inquire about this report at http//www.marketopti
    mizer.org/contacts/purchase?rname7292

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
4
Safinamide (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • Scope
  • Overview of Parkinsons disease, including
    epidemiology, etiology, symptoms, diagnosis,
    pathology and treatment guidelines as well as an
    overview on the competitive landscape.
  • Detailed information on Safinamide including
    product description, safety and efficacy profiles
    as well as a SWOT analysis.
  • Sales forecast for Safinamide for the top seven
    countries from 2012 to 2022.
  • Sales information covered for the US, France,
    Germany, Italy, Spain, the UK and Brazil.

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
5
Safinamide (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • Reasons to buy
  • Understand and capitalize by identifying products
    that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding
    the changing competitive landscape for
    Parkinsons disease
  • Effectively plan your MA and partnership
    strategies by identifying drugs with the most
    promising sales potential
  • Make more informed business decisions from
    insightful and in-depth analysis of Safinamide
    performance
  • Obtain sales forecast for Safinamide from
    2012-2022 in the top seven countries (the US,
    France, Germany, Italy, Spain, the UK and
    Brazil).
  •  
  • Get a detailed report at http//www.marketoptimize
    r.org/safinamide-parkinsons-disease-forecast-and-m
    arket-analysis-to-2022.html .

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
6
Safinamide (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • About Us
  • marketoptimizer.org is an online market research
    reports library of 250,000 in-depth studies of
    over 5000 micro markets. Our database includes
    reports by leading publishers from across the
    globe. We provide 24/7 online and offline support
    service to our customers. marketoptimizer.org
    also offers company data, country profiles,
    trends, information and analysis on the sector of
    your interest.
  • Visit Us _at_
  • http//www.marketoptimizer.org
  • Follow Us

Call Now 1 888 391 5441 Email sales _at_
sales_at_marketoptimizer.org
About PowerShow.com